HUP0304093A3 - Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them - Google Patents

Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them

Info

Publication number
HUP0304093A3
HUP0304093A3 HU0304093A HUP0304093A HUP0304093A3 HU P0304093 A3 HUP0304093 A3 HU P0304093A3 HU 0304093 A HU0304093 A HU 0304093A HU P0304093 A HUP0304093 A HU P0304093A HU P0304093 A3 HUP0304093 A3 HU P0304093A3
Authority
HU
Hungary
Prior art keywords
antineoplastic
pharmaceutical compositions
mtor inhibitor
antimetabolic
compositions containing
Prior art date
Application number
HU0304093A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HUP0304093A2 publication Critical patent/HUP0304093A2/hu
Publication of HUP0304093A3 publication Critical patent/HUP0304093A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0304093A 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them HUP0304093A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238801P 2001-04-06 2001-04-06
US28238501P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (2)

Publication Number Publication Date
HUP0304093A2 HUP0304093A2 (hu) 2004-04-28
HUP0304093A3 true HUP0304093A3 (en) 2008-08-28

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0304093A HUP0304093A3 (en) 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them

Country Status (21)

Country Link
EP (1) EP1385551B1 (enExample)
JP (1) JP2004525950A (enExample)
KR (1) KR100862178B1 (enExample)
CN (1) CN1309421C (enExample)
AT (1) ATE406892T1 (enExample)
AU (1) AU2007242958A1 (enExample)
BR (1) BR0208627A (enExample)
CA (1) CA2442849A1 (enExample)
DE (1) DE60228699D1 (enExample)
EA (1) EA010184B1 (enExample)
ES (1) ES2312568T3 (enExample)
HU (1) HUP0304093A3 (enExample)
IL (1) IL157898A0 (enExample)
MX (1) MXPA03009092A (enExample)
NO (1) NO20034433L (enExample)
NZ (1) NZ540047A (enExample)
PL (1) PL363991A1 (enExample)
PT (1) PT1385551E (enExample)
SG (1) SG152906A1 (enExample)
SI (1) SI1385551T1 (enExample)
WO (1) WO2002080975A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
CA2557504C (en) * 2004-02-26 2020-12-01 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PT2275103E (pt) * 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
JP2009523149A (ja) * 2006-01-12 2009-06-18 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
JP2009539769A (ja) * 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
JP5919593B2 (ja) * 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
EP3417859A1 (en) * 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
NZ540047A (en) 2007-01-26
IL157898A0 (en) 2004-03-28
SI1385551T1 (sl) 2008-12-31
SG152906A1 (en) 2009-06-29
PT1385551E (pt) 2008-11-03
MXPA03009092A (es) 2004-02-12
DE60228699D1 (de) 2008-10-16
BR0208627A (pt) 2004-03-09
ATE406892T1 (de) 2008-09-15
WO2002080975A1 (en) 2002-10-17
EA200301091A1 (ru) 2004-02-26
NO20034433D0 (no) 2003-10-03
EA010184B1 (ru) 2008-06-30
HK1060062A1 (en) 2004-07-30
EP1385551B1 (en) 2008-09-03
KR100862178B1 (ko) 2008-10-09
NO20034433L (no) 2003-11-25
AU2007242958A1 (en) 2008-01-10
KR20040007491A (ko) 2004-01-24
CN1309421C (zh) 2007-04-11
CN1545419A (zh) 2004-11-10
HUP0304093A2 (hu) 2004-04-28
ES2312568T3 (es) 2009-03-01
CA2442849A1 (en) 2002-10-17
PL363991A1 (en) 2004-11-29
JP2004525950A (ja) 2004-08-26
EP1385551A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
HUP0304093A2 (hu) Daganatellenes hatású, egy mTOR gátlót és egy antimetabolit daganatellenes szert tartalmazó kombinációk és ezeket tartalmazó gyógyszerkészítmények
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
HUP0400114A3 (en) N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL156716A0 (en) Pharmaceutical formulation
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
PT1461039E (pt) Composições farmacêuticas compreendendo cilostazol e um inibidor da captação de adenosina
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
GB0111597D0 (en) Pharmaceutical compositions
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
GB0118689D0 (en) Pharmaceutical formulation
HUP0400521A3 (en) Use of cci-779 as an antineoplastic agent
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
PL366432A1 (en) Pharmaceutical formulation
IL159591A0 (en) Pharmaceutical compositions containing terbinafin and use thereof
IL158236A0 (en) Pharmaceutical compositions containing azithromycin and derivatives thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU2002254455A1 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees